Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2

dc.contributor.author	Vázquez Estévez, Sergio
dc.date.accessioned	2017-06-07T06:54:39Z
dc.date.available	2017-06-07T06:54:39Z
dc.date.issued	2012
dc.identifier.issn	0959-4973
dc.identifier.uri	http://hdl.handle.net/20.500.11940/493
dc.language.iso	eng
dc.title	Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2
dc.type	Artigo	es
dc.authorsophos	Servitja S.
dc.authorsophos	Ramos M.
dc.authorsophos	Gil M.
dc.authorsophos	Sanchez-Rovira P.
dc.authorsophos	Vazquez-Estevez S.
dc.authorsophos	Virizuela J.A.
dc.authorsophos	Garcia-Estevez L.
dc.authorsophos	Velasco A.
dc.authorsophos	Tusquets I.
dc.identifier.doi	http://dx.doi.org/10.1097/CAD.0b...
dc.identifier.sophos	11424
dc.issue.number	2
dc.journal.title	ANTI-CANCER DRUGS
dc.organization	Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Lugo - Hospital Universitario Lucus Augusti::Oncoloxía médica
dc.page.final	485
dc.rights.accessRights	openAccess
dc.typesophos	Artículo Original
dc.volume.number	23

Ficheros en el ítem

Ficheros	Tamaño	Formato	Ver
No hay ficheros asociados a este ítem.